| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... The Lancet 389 (10064), 56-66, 2017 | 3728 | 2017 |
| A placebo-controlled trial of bezafibrate in primary biliary cholangitis C Corpechot, O Chazouillères, A Rousseau, A Le Gruyer, F Habersetzer, ... New England Journal of Medicine 378 (23), 2171-2181, 2018 | 529 | 2018 |
| Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3‐and 6‐month periodicities JC Trinchet, C Chaffaut, V Bourcier, F Degos, J Henrion, H Fontaine, ... Hepatology 54 (6), 1987-1997, 2011 | 466 | 2011 |
| Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial JM Perarnau, A Le Gouge, C Nicolas, L d’Alteroche, P Borentain, F Saliba, ... Journal of hepatology 60 (5), 962-968, 2014 | 248 | 2014 |
| Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea R Gloro, I Hourmand-Ollivier, B Mosquet, L Mosquet, P Rousselot, ... European journal of gastroenterology & hepatology 17 (10), 1135-1137, 2005 | 184 | 2005 |
| RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled … J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... Lancet 389 (10064), 56-66, 2017 | 174 | 2017 |
| Effects of long-term norfloxacin therapy in patients with advanced cirrhosis R Moreau, L Elkrief, C Bureau, JM Perarnau, T Thévenot, F Saliba, ... Gastroenterology 155 (6), 1816-1827. e9, 2018 | 155 | 2018 |
| EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice C Aubé, F Oberti, J Lonjon, G Pageaux, O Seror, G N'Kontchou, A Rode, ... Liver International 37 (10), 1515-1525, 2017 | 150 | 2017 |
| Long term highly saturated fat diet does not induce NASH in Wistar rats C Romestaing, MA Piquet, E Bedu, V Rouleau, M Dautresme, ... Nutrition & metabolism 4, 1-14, 2007 | 121 | 2007 |
| Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy S Lhomme, N Kamar, F Nicot, J Ducos, M Bismuth, V Garrigue, ... Antimicrobial agents and chemotherapy 60 (3), 1608-1614, 2016 | 92 | 2016 |
| Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management J Ehtisham, M Altieri, E Salamé, E Saloux, I Ollivier, M Hamon Liver Transplantation 16 (5), 550-557, 2010 | 92 | 2010 |
| Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma JL Jouve, T Lecomte, O Bouché, E Barbier, FK Akouz, G Riachi, EN Khac, ... Journal of hepatology 71 (3), 516-522, 2019 | 82 | 2019 |
| Cardiac sources of embolism should be routinely screened in ischemic colitis I Hourmand-Ollivier, M Bouin, E Saloux, R Morello, P Rousselot, ... Official journal of the American College of Gastroenterology| ACG 98 (7 …, 2003 | 77 | 2003 |
| LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized … J Bruix, P Merle, A Granito, YH Huang, G Bodoky, O Yokosuka, ... Annals of Oncology 27, ii140, 2016 | 74 | 2016 |
| Mitochondrial adaptations to steatohepatitis induced by a methionine-and choline-deficient diet C Romestaing, MA Piquet, D Letexier, B Rey, A Mourier, S Servais, ... American Journal of Physiology-Endocrinology and Metabolism 294 (1), E110-E119, 2008 | 61 | 2008 |
| A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical … C Corpechot, O Chazouillères, A Rousseau, D Guyader, F Habersetzer, ... Journal of Hepatology 66 (1, S), S89, 2017 | 59 | 2017 |
| Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial P Merle, JF Blanc, JM Phelip, G Pelletier, JP Bronowicki, Y Touchefeu, ... The Lancet Gastroenterology & Hepatology 4 (6), 454-465, 2019 | 55 | 2019 |
| Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. J Bruix, P Merle, A Granito, YH Huang, G Bodoky, O Yokosuka, ... Journal of Clinical Oncology 36 (4_suppl), 412-412, 2018 | 52 | 2018 |
| The epidemiology of Budd–Chiari syndrome in France I Ollivier-Hourmand, M Allaire, N Goutte, R Morello, C Chagneau-Derrode, ... Digestive and Liver Disease 50 (9), 931-937, 2018 | 51 | 2018 |
| Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score E De Martin, A Coilly, O Chazouillères, O Roux, JM Peron, ... Journal of Hepatology 74 (6), 1325-1334, 2021 | 46 | 2021 |
